Theratechnologies reports data showing high expression of sortilin (SORT1) in multiple solid… | National

Theratechnologies reports data showing high expression of sortilin (SORT1) in multiple solid… |  National

  • Poster for presentation at3. 4theEORTC-NCI-AACR Symposiumon molecular targets and cancer therapies improves understanding of SORT1 expression in healthy and tumor tissues
  • Extensive data set underscores the potential of SORT1 as a new therapeutic target against cancer

MONTREAL, Oct. 26, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on developing and commercializing therapeutic reports groundbreaking data from a tissue microarray (TMA) study demonstrating high expression of sortilin 1 (SORT1) in various solid tumors compared to normal tissues, to be presented as a poster at the 34th European Organization for Research and Treatment of Cancer (EORTC), the The National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) Symposium on Molecular Targets and Cancer Therapies will be held October 26-28, 2022 at Barcelona, ​​Spain. The data highlights the potential of SORT1 as a novel target for internalization of cancer therapy and will be used to support the Theratechnologies’ SORT1+ Technology™ platform’s ongoing preclinical and clinical programs.

SORT1 is a receptor protein that binds to circulating proteins and peptides prior to their intracellular internalization. Participates in the rapid transport of molecules through the cell membrane. The internalization function of SORT1 can be harnessed to internalize a peptide-drug conjugate (PDC) to which docetaxel binds and potentially inhibit cancer cell proliferation. Until now, the pattern and prevalence of SORT1 expression in different healthy tissues have not been well understood, but SORT1 has been shown to be highly expressed in certain malignancies such as breast and ovarian cancer.

“Our study, the first to assess SORT1 expression in a variety of tissue microarrays representing various malignancies, shows that this receptor is highly expressed in cancer compared to normal tissues,” said Christian Marsolais, Ph.D. ., Senior Vice President and Chief Medical Officer. Officer, Theratechnologies. “To our knowledge, no other group has carried out such an extensive screening of tumor or normal tissue biopsies to assess the expression level of SORT1, which is elevated in multiple tumor types and is maintained in stages 1 to 4. That makes SORT1 an attractive receptor for targeted delivery and rapid internalization of cancer therapeutics.”

The researchers reported data on a total of 1,446 cancer cores, using the same immunohistochemistry (IHC) method, and scored them using an H-score (an accurate method of describing reactivity in homogeneous tissue such as cancer) ranging from 0 to 300. , where 0 corresponds to no cells stained for SORT1 and 300 corresponds to strong SORT1 staining in all cells.

The researchers observed high expression of SORT1 in multiple solid tumors, as illustrated in the following table:

tumor type Evaluable Cases (n) % indication with H-score ≥100 Average H-score
Non-Triple Negative Breast Cancer (TNBC) 195 88 159
TNBC 171 70 135
Ovarian cancer 249 75 142
endometrial cancer 101 85 169
Melanoma 162 88 166
colorectal cancer 201 54 98
pancreatic cancer 178 26 54

Interestingly, in 257 evaluable nuclei from normal or adjacent tissue, SORT1 staining was negative (null) or low for most healthy tissues, including lung, stomach, liver, ovary, prostate, lymph node, esophagus, small intestine, cervix, skin, spleen, bone marrow, and thymus. Some healthy tissues had moderate or strong staining in >10% of cells, including colonic mucosa, rectal epithelium, pancreatic islets and vessels, mammary lobules, testicular spermatids and Sertoli cells, renal tubules, and brain neuronal cells and astrocytes. The full poster can be found at Theratechnologies’ website.

“These findings further strengthen the evidence to support the development of our SORT1+ Technology™ platform, including our first ongoing human study of TH1902, a SORT1-targeted PDC, currently in eight types of solid tumors,” added Dr. Marsolais. . “They could also lay the groundwork for additional PDCs that are in early development.”

The company intends to further evaluate additional tissue microarrays to increase biopsy sample size and broaden the range of tumor types and subtypes that may be susceptible to SORT1, such as prostate, small cell lung carcinoma and thyroid cancers.

About TH1902 and SORT1+ Technology™

Theratechnologies is currently developing a proprietary peptide platform called SORT1+ TechnologyTM for the development of anticancer drugs targeting SORT1 receptors. The SORT1 receptor plays an important role in protein internalization, sorting, and trafficking. It is highly expressed in cancer cells compared to healthy tissue, making SORT1 an attractive target for anticancer drug development. SORT1 expression is associated with aggressive disease, poor prognosis, and decreased survival. It is estimated that the SORT1 receptor is expressed in 40% to 90% of cases of endometrial, ovarian, colorectal, triple-negative breast, and pancreatic cancer.

TH1902 is currently Theratechnologies’ lead investigational PDC candidate for cancer treatment derived from its SORT1+ Technology™. It is the Company’s proprietary peptide linked to docetaxel, a cytotoxic agent commonly used to treat many types of cancer. The US FDA granted fast track designation to TH1902 as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies that address unmet medical needs. More information about Theratechnologies is available on the Company’s website at www.theratech.comon SEDAR at sedar.com and in EDGAR in www.sec.gov.

forward-looking information

This press release contains forward-looking statements and forward-looking information (collectively, “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on the beliefs and assumptions of our management and information currently available to our management. You can identify Forward-Looking Statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “anticipate”, “anticipate”, “expect”. ” and “estimate”, or the negatives of these terms, or variations of them. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the SORT1 protein as a new target for internalization of cancer therapy, the development of our SORT1+ TechnologyTM platform, the conduct of our clinical trial with TH1902, and our intention to evaluate additional tissue microarrays. Although the Forward-Looking Statements contained in this press release are based on what the Company believes to be reasonable assumptions in light of currently available information, investors are cautioned not to place undue reliance on these statements as actual results may vary from the Forward-Looking Statements. . Certain assumptions made in preparing the Forward-Looking Statements include that: the preclinical results obtained using TH1902 will replicate in humans, SORT1 is a receptor to target for delivering anticancer therapeutics, TH1902 will prove safe and effective in humans, and continuing to evaluate microarrays of knitting. Assumptions in Forward-Looking Statements are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control and could cause actual results to differ materially from those disclosed or implied by such Forward-Looking Statements. These risks and uncertainties include, but are not limited to, the risk that SORT1 may not be the appropriate target for delivering cancer therapeutics, we see no signs of efficacy using TH1902 in our phase 1 clinical trial, and serious adverse side effects are associated. with the administration of TH1902. We refer current and prospective investors to the “Risk Factors” section of our Annual Information Form dated February 23, 2022 available on SEDAR at sedar.com and in EDGAR in www.sec.gov as an exhibit to our report on Form 40-F dated February 24, 2022 under Theratechnologies’ public filings for additional risks related to the Company. The reader is cautioned to consider these and other risks and uncertainties carefully and not to place undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as required by applicable law.

contacts:

Media Inquiries:

julie schneiderman

Senior Director, Communications and Corporate Affairs

communications@theratech.com

1-514-336-7800

Investor inquiries:

elif mcdonald

Senior Director, Investor Relations

go@theratech.com

1-438-315-8563

Leave a Comment